Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: A meta-analysis consisting of 1314 patients

Melanoma Research

Volumn 23, Issue 5, 2013, Pages 381-389

  Teimouri, Fatemeh ^a   Nikfar, Shekoufeh ^a,c   Abdollahi, Mohammad ^b  

^a Faculty of Pharmacy ^*  (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

Author keywords

Dacarbazine; Efficacy; Malignant melanoma; Meta analysis; Side effects; Systematic review; Temozolomide

Indexed keywords

CISPLATIN; DACARBAZINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TEMOZOLOMIDE; ALKYLATING AGENT;

ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; COMPARATIVE EFFECTIVENESS; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; FATIGUE; FEVER; HEART DISEASE; HUMAN; LEUKOCYTE; LEUKOPENIA; LIVER FUNCTION; LYMPHOCYTOPENIA; MELANOMA; META ANALYSIS; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PAIN; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; ODDS RATIO; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RISK FACTOR; SKIN NEOPLASMS; TIME; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DISEASE PROGRESSION; HUMANS; MELANOMA; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887990673     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3283649a97     Document Type: Article

References (21)

1. Slipicevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Ups J Med Sci 2012; 117:237-243.
2. Sober AJ, Tsao H, Washington CV. Cancer of the skin. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison's principles of internal medicine. 17th ed. Blacklick: McGraw-Hill; 2008. pp. 541-548.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program. Washington, DC: National Cancer Institute; 2005.
4. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004; 150: 179-185.
5. Hamm C, Verma S, Petrella T, Bak K, Charette M. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 2008; 34:145-156.
6. Clark MA, Finkel R, Rey JA, Whalen K. Anticancer drugs. In: Harvey RA, editor. Pharmacology. 5th ed. Blacklick: Lippincott Williams & Wilkins; 2011. pp. 481-513.
7. Missailidis S. Anticancer therapeutics. 1st ed. Chichester: Wiley-Blackwell; 2008. pp. 149-152.
8. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2001; 2:552-560.
9. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16:5-24.
10. Jadad AR. Randomised controlled trials: a users guide. London: BMJ Books; 1998.
11. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
12. Chiarion-sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J, et al. Central nervous system failure in melanoma patients: results of a randomized, multicentre phase 3 study of temozolomide and dacarbazinebased regimens. Br J Cancer 2011; 104:1816-1821.
13. Patel PM, Suciu S, Mortier L, Kruit WH, Robert C, Schadendorf D, et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomized phase III study (EORTC 18032). Eur J Cancer 2011; 47:1476-1483.
14. Tredudler R, Georgieva J, Geilen CC, Orfanos CE. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. J Am Acad Dermatol 2004; 50:783-785.
15. Kim C, Lee CW, Kovacic L, Shah A, Klasa R, Savage KJ. Long-term survival in patients with metastatic melanoma treated with dacarbazine or temozolomide. Oncologist 2010; 15:765-771.
16. Abdollahiasl A, Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M. A model for developing a decision support system to simulate national drug policy indicators. Arch Med Sci 2011; 7:744-746.
17. Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M. Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. BMC Int Health Hum Rights 2005; 5:510.
18. Cheraghali AM, Nikfar S, Behmanesh Y, Rahimi V, Habibipour F, Tirdad R, et al. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran. East Mediterr Health J 2004; 10:406-415.
19. Nikfar S, Khatibi M, Abdollahiasl A, Abdollahi M. Cost and utilization study of antidotes: an Iranian experience. Int J Pharmacol 2011; 7:46-49.
20. Nikfar S. A new model for decision analysis in economic evaluations of switchable health interventions. J Med Hypotheses Ideas 2012; 6:12-15.
21. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007; 12:1114-1123.